FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394958> ?p ?o ?g. }

• W4308394958 abstract "<h3>Background</h3> Pancreatic ductal adenocarcinoma (PDAC) features a dense, fibrotic stroma that obstructs infiltration of immune cells. Our group investigates methods to improve immunotherapy efficacy in PDAC by targeting and manipulating the PDAC stroma. We hypothesize that dysregulated CD26/DPP4 enzymatic activity in PDAC contributes to constrained efficacy of immunotherapy. In addition, we postulate that in vivo pharmacological targeting of CD26 enzyme activity in PDAC, via inhibitors that are FDA-approved for adult patients with Type 2 Diabetes Mellitus, can influence immune cell infiltration and enhance responses to immune checkpoint blockade in murine models of PDAC. <h3>Methods</h3> CD26 protein expression was evaluated in immortalized CAFs and PDAC cells by immunoblot and flow cytometry, while soluble CD26 was measured in supernatants by ELISA. In vivo studies used immune-competent C57BL/6 mice orthotopically implanted with syngeneic luciferase-expressing KPC-tumor cells into the pancreas. Tumor establishment was verified by bioluminescence imaging (BLI). Mice were randomized to the following treatment groups: sitagliptin (75mg/kg in drinking water, CD26/DPP4 inhibitor), anti-PD-L1 Ab (200 ug 3x/week), or both combined for 9 days. Controls received vehicle and/or isotype control Ab. BLI monitored tumor growth throughout the study. Tumors were harvested and weighed at study endpoint (day 9 of treatment) and immune cell infiltration was evaluated by flow cytometry. An additional in vivo study was performed to assess differences in efficacy of concurrent versus consecutive administration (2 weeks) of sitagliptin (75mg/kg) and anti-PD-L1 Ab by measuring BLI and pancreas weight at study endpoint. <h3>Results</h3> CD26 protein expression was observed in both immortalized human CAFs (HT137 and h-iPSC-PDAC-1) and PDAC cells (HPAC and PANC1) through immunoblot and flow cytometry, however soluble CD26 was only detected in CAF supernatants. Concurrent administration of sitagliptin and anti-PD-L1 Ab limited tumor progression and increased tumor infiltrating CD4+ T cells (p=.0302, p=.0208 vs isotype control and anti-PD-L1, respectively), CD8+ T cells (p=.0336 vs anti-PD-L1), and macrophages compared to vehicle, sitagliptin, and anti-PD-L1 Ab alone. Further studies showed no significant difference in efficacy between concurrent and consecutive administration of sitagliptin together with anti-PD-L1 Ab. <h3>Conclusions</h3> Our results reveal that CD26 enzyme inhibition (sitagliptin), augments anti-tumor activity of anti-PD-L1 Ab in PDAC tumor-bearing mice. This work identifies immune cell populations, including T cells and macrophages, that provide insight into mechanisms of efficacy in orthotopic murine models of PDAC. Continued investigations will evaluate the versatility of CD26 inhibition and its capacity to modulate immune checkpoint molecules, thus, broadening efficacy studies across other targets with relevance to PDAC." @default.
• W4308394958 created "2022-11-11" @default.
• W4308394958 creator A5003348560 @default.
• W4308394958 creator A5014062413 @default.
• W4308394958 creator A5027872333 @default.
• W4308394958 creator A5029499310 @default.
• W4308394958 creator A5031694093 @default.
• W4308394958 creator A5032094154 @default.
• W4308394958 creator A5044271217 @default.
• W4308394958 creator A5057176768 @default.
• W4308394958 creator A5057476943 @default.
• W4308394958 creator A5068851994 @default.
• W4308394958 date "2022-11-01" @default.
• W4308394958 modified "2023-09-23" @default.
• W4308394958 title "1457 The role of CD26 in pancreatic ductal adenocarcinoma" @default.
• W4308394958 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1457" @default.
• W4308394958 hasPublicationYear "2022" @default.
• W4308394958 type Work @default.
• W4308394958 citedByCount "0" @default.
• W4308394958 crossrefType "proceedings-article" @default.
• W4308394958 hasAuthorship W4308394958A5003348560 @default.
• W4308394958 hasAuthorship W4308394958A5014062413 @default.
• W4308394958 hasAuthorship W4308394958A5027872333 @default.
• W4308394958 hasAuthorship W4308394958A5029499310 @default.
• W4308394958 hasAuthorship W4308394958A5031694093 @default.
• W4308394958 hasAuthorship W4308394958A5032094154 @default.
• W4308394958 hasAuthorship W4308394958A5044271217 @default.
• W4308394958 hasAuthorship W4308394958A5057176768 @default.
• W4308394958 hasAuthorship W4308394958A5057476943 @default.
• W4308394958 hasAuthorship W4308394958A5068851994 @default.
• W4308394958 hasBestOaLocation W43083949581 @default.
• W4308394958 hasConcept C121608353 @default.
• W4308394958 hasConcept C126322002 @default.
• W4308394958 hasConcept C150903083 @default.
• W4308394958 hasConcept C203014093 @default.
• W4308394958 hasConcept C204232928 @default.
• W4308394958 hasConcept C207001950 @default.
• W4308394958 hasConcept C2777701055 @default.
• W4308394958 hasConcept C2778764654 @default.
• W4308394958 hasConcept C2780210213 @default.
• W4308394958 hasConcept C502942594 @default.
• W4308394958 hasConcept C52124034 @default.
• W4308394958 hasConcept C553184892 @default.
• W4308394958 hasConcept C71924100 @default.
• W4308394958 hasConcept C86803240 @default.
• W4308394958 hasConcept C8891405 @default.
• W4308394958 hasConceptScore W4308394958C121608353 @default.
• W4308394958 hasConceptScore W4308394958C126322002 @default.
• W4308394958 hasConceptScore W4308394958C150903083 @default.
• W4308394958 hasConceptScore W4308394958C203014093 @default.
• W4308394958 hasConceptScore W4308394958C204232928 @default.
• W4308394958 hasConceptScore W4308394958C207001950 @default.
• W4308394958 hasConceptScore W4308394958C2777701055 @default.
• W4308394958 hasConceptScore W4308394958C2778764654 @default.
• W4308394958 hasConceptScore W4308394958C2780210213 @default.
• W4308394958 hasConceptScore W4308394958C502942594 @default.
• W4308394958 hasConceptScore W4308394958C52124034 @default.
• W4308394958 hasConceptScore W4308394958C553184892 @default.
• W4308394958 hasConceptScore W4308394958C71924100 @default.
• W4308394958 hasConceptScore W4308394958C86803240 @default.
• W4308394958 hasConceptScore W4308394958C8891405 @default.
• W4308394958 hasLocation W43083949581 @default.
• W4308394958 hasOpenAccess W4308394958 @default.
• W4308394958 hasPrimaryLocation W43083949581 @default.
• W4308394958 hasRelatedWork W2005812634 @default.
• W4308394958 hasRelatedWork W2220916195 @default.
• W4308394958 hasRelatedWork W2359951467 @default.
• W4308394958 hasRelatedWork W2600123923 @default.
• W4308394958 hasRelatedWork W2810246221 @default.
• W4308394958 hasRelatedWork W2898379310 @default.
• W4308394958 hasRelatedWork W2999717614 @default.
• W4308394958 hasRelatedWork W3027333363 @default.
• W4308394958 hasRelatedWork W3028822667 @default.
• W4308394958 hasRelatedWork W4362529736 @default.
• W4308394958 isParatext "false" @default.
• W4308394958 isRetracted "false" @default.
• W4308394958 workType "article" @default.